Trial of ZW25 in Patients With Advanced HER2-expressing Cancers

Update Il y a 4 ans
Reference: NCT02892123

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the maximal tolerated dose (MTD), optimal biological dose (OBD) or other recommended dose (RD), and overall safety and tolerability of ZW25, a humanized bispecific monoclonal antibody targeting the extracellular domain of HER2, in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers.


Inclusion criteria

  • HER2-expressing Cancers

Links